A previous report demonstrated that AP-2a favors the survival of ovarian cancer patients by clinical findings. However, the functional roles of AP-2a in human ovarian cancers have not been determined. To clarify the roles, we overexpressed AP-2a in SKOV3 human ovarian cancer cells, which originally possess little AP-2a. AP-2a overexpression changed cell morphology from spindle to epithelioid type and suppressed cell proliferation and invasion, which would be partially correlated with decreased phosphorylation levels of the erbB2, Akt and ERK pathways, increased E-cadherin and reduced pro-matrix metalloproteinase-2 levels. Moreover, nude mice intraperitoneally injected with AP-2a-overexpressing cells survived longer than those with neotransfected cells. The present data represent the first direct evidence that AP-2a plays a tumor suppressive role in ovarian cancer.
Introduction
Epithelial ovarian cancer remains the most lethal gynecological malignancy, despite the introduction of new surgical and chemotherapeutic regimens. Poor survival rates are mainly associated with late diagnosis attributable to clinically silent tumorigenesis, as suggested by the fact that most patients already display intraperitoneal dissemination at the time of initial diagnosis (Kikkawa et al., 2000; Davidson, 2001) . To improve prognosis for ovarian cancer patients, elucidating the molecular mechanisms of metastasis and progression of cancer and developing new therapeutic tools based on these mechanisms are required. Transcriptional factors, capable of coordinating gene expression, have been implicated in the pathogenesis of malignancy, which would serve as novel therapeutic targets.
AP-2 is a eukaryotic transcription factor that is required for normal development and morphogenesis during vertebrate embryogenesis. The AP-2 family comprises at least four isoforms of 52 kDa proteins, encoded by independent genes AP-2a, AP-2b, AP-2g and AP-2d, located on chromosome 6p24, 6p12, 20q13 and 6p12-p21.1, respectively (Gaynor et al., 1991; Williamson et al., 1996; Moser et al., 1997; Zhao et al., 2001) . Although these family members besides AP-2d bind indistinguishably to target DNA as homo-or hetero-dimers, they are individually associated with cell differentiation and development. Analysis by homologous deletion in mice has suggested an important role of AP-2a in the development of the neural tube and craniofacial tissues (Zhang et al., 1996) , AP-2b in terminal kidney differentiation (Moser et al., 1997) , and AP-2g in proliferation and differentiation of extraembryonic lineages (Auman et al., 2002) . AP-2d were cloned in 2001 (Zhao et al., 2001) , but its role has not been defined yet.
It has been also reported that AP-2 plays a significant role in the progression or regression of cancer. For example, loss of AP-2 expression results in the transition of melanoma cells to the metastatic phenotype (Bar-Eli, 2001; Gershenwald et al., 2001) , indicating that AP-2 plays a suppressive role in cancer development. On the contrary, in breast cancer, AP-2 has been shown to be involved in inducing proto-oncogenes erbB2 and erbB3 (Zhu and Domann, 2002; Vernimmen et al., 2003) leading to the increase in the malignancy potential. Contrary to the well-documented transcription factors encoding oncogenes such as c-myc (Orsulic et al., 2002) and K-ras (Enomoto et al., 1990) , which are involved in carcinogenesis and expansion of cancer, these reports suggest that the AP-2 gene family may display various effects in cancer development in a tissue-specific manner.
For epithelial ovarian cancer, immunohistochemical analysis has revealed that high AP-2a expression is related to significant survival advantage (Anttila et al., 2000) , although the functional roles in ovarian cancer remain unclear. These findings prompted us to clarify the fundamental roles of AP-2a in human ovarian cancer. To achieve this goal, AP-2a expression was first examined in five ovarian cancer cell lines. Then we overexpressed AP-2a in SKOV3 cells, which originally possess little AP-2a, and evaluated the changes in growth and invasion ability compared with parental cells. To investigate the underlying mechanisms of the changes, we also analysed E-cadherin expression and matrix metalloproteinase (MMP)-2 activity. AP-2 has also been shown to contribute to the overexpression of erbB2, a member of the erbB family of type I receptor tyrosine kinases, in breast cancer cells Vernimmen et al., 2003) , and overexpression of erbB2 is correlated with a poorer clinical outcome in a variety of malignancies (Slamon, 1987; Bacus et al., 1994) . However, the molecular mechanisms leading to erbB2 gene overexpression in nonbreast cancer cells, including ovarian cancer cells, remain unclear. Thus, we examined whether AP-2a overexpression affected erbB2 expression. ErbB2 overexpression is associated with the activation of downstream pathways involved in survival (phosphatidylinositol 3-kinase/Akt) and cell proliferation (mitogen-activated protein kinases or MAPK; also known as ERK1/2) (Egan and Weinberg, 1993; Kavanaugh and Williams, 1994; Luttrell et al., 1994; Levkowitz et al., 1996; Olayioye et al., 1998; Daly, 1999; Klapper et al., 2000) . We also analysed the activity of those pathways in AP-2a-overexpressed cells compared to that in neo-transfectants. The malignant potential of AP-2a transfectants was also assessed in vivo by injecting the cells into nude mice. This study offers the first evidence that AP-2a plays a tumor suppressive role in ovarian cancer, both in vitro and in vivo.
Results

AP-2a endogenous expression in ovarian cancer cell lines
We used five human ovarian cancer cell lines (SKOV3, HRA, TAOV, NOS2 and NOS4) derived from serous adenocarcinoma. To evaluate expression levels of AP-2a in these ovarian cancer cell lines, wholecell extracts were obtained and Western blot analysis was performed. The 52 kDa protein was detected in all cell lines. TAOV, NOS2 and NOS4 cells displayed high expression of AP-2a protein, while SKOV3 and HRA cells showed poor expression. The b-actin proteins were almost the same level among these cell lines (Figure 1a ). In addition, morphology of cell lines with high AP-2a expression tended to show epithelioid patterns, contrasting with cell lines with poor AP-2a expression, which showed long spindle/bipolar patterns like fibroblasts (Figure 1b) .
Overexpression of AP-2a in SKOV3 cells and morphological change after AP-2a transfection
To investigate the roles of AP-2a in ovarian cancer, AP2a was overexpressed in ovarian cancer SKOV3 cells, which originally display poor expression, by stable transfection with the AP-2a expression vector. Following transfection, 20 transfectants were obtained and two independent clones of these were used (SKAP2 clones 1 and 2). Western blot analysis using anti-AP-2a antibody demonstrated high levels of AP-2a proteins in the two transfectants, but not in either parental (SKOV3) or neo-transfected (SKpSG5) cells (Figure 2a ). To further determine whether AP-2a was transcriptionally active in SKAP2 cells, chloramphenicol acetyltransferase (CAT) enzyme assay was performed (Figure 2b ). CAT activity was remarkably increased in both SKAP2 clones 1 and 2 when they were transfected with A2BCAT (containing consensus AP-2a binding sites) compared with that in BCAT (containing no AP-2a binding sites). SKOV3 and SKpSG5 cells showed low CAT activity, even with A2BCAT. Interestingly, marked morphological changes were observed in SKAP2 cells. Parental SKOV3 cells 
Proliferation assay in vitro
The effect of AP-2a overexpression on cell proliferation was then assessed. In the modified tetrazolium salt (MTS) proliferation assay, SKpSG5 cells did not differ significantly from SKOV3 cells, while SKAP2 cells (clones 1 and 2) demonstrated slight but significant growth inhibition (vs SKOV3, 76.176.4% (clone 1) and 79.379.7% (clone 2); Figure 4a ; Po0.01). Therefore, to verify the results of the MTS assays, we also detected DNA synthesis cytochemically by exposing cells to 5-bromo-2 0 -deoxyuridine (BrDU). In accordance with the MTS assay, the DNA synthesis of SKAP2 cells (clones 1 and 2) was significantly decreased compared to that in SKOV3 and SKpSG5 cells (vs SKOV3, 78.074.3% (clone 1) and 75.973.9% (clone 2); Figure 4b ; Po0.01).
These results demonstrated that AP-2a inhibited cell growth mildly.
Invasion assay in vitro
Cell invasion was evaluated using 24-well Matrigel invasion chambers with 5.0% fetal calf serum (FCS) as a chemoattractant at 15 h. Figure 5a shows that SKOV3 and SKpSG5 cells displayed high potential to penetrate matrigel-coated filters. In contrast with it, SKAP2 cells (clones 1 and 2) displayed markedly reduced invasiveness ( Figure 5a ). Numbers of invading cells were significantly smaller for SKAP2 clones 1 and 2 than for SKOV3 or SKpSG5 cells (vs SKOV3, 4.172.7% (clone 1) and 4.372.1% (clone 2); Figure 5b ; Po0.01).
Effect of AP-2a overexpression on E-cadherin expression and MMP activity
To resolve the mechanisms underlying low invasiveness of SKAP2 cells, changes in E-cadherin expression and MMP activity were next examined. Western blot analysis revealed an apparent increase in E-cadherin expression in SKAP2 cells (clone 1) compared to SKOV3 and SKpSG5 cells (Figure 6a ). SKAP2 (clone 2) cells showed results similar to that obtained by SKAP2 (clone 1) (data not shown). Then we performed the gelatin zymography with the conditioned medium (CM) at 24 h, which demonstrated that pro-MMP-2 activity was reduced in SKAP2 cells (clones 1 and 2) compared to SKOV3 and SKpSG5 cells (Figure 6b ). The active forms of MMP-2 and pro-MMP-9 were detected, but were so weak by that we were unable to compare the density of the bands. At 28 days, the last mouse in the SKpSG5 group died and was anatomized to observe the intra-abdominal appearance. At the same time, a mouse in the SKAP2 group was killed for comparison. The mouse injected with SKpSG5 cells displayed a number of disseminated and enlarged tumors throughout the entire peritoneal cavity, particularly on the omentum and mesentery, with large amounts of bloody ascites. In contrast, the mouse injected with SKAP2 cells possessed a small number of small tumors with a small amount of ascites. As shown in Table 1 , both the diameter and total weight of disseminated tumors in the SKpSG5-injected mouse were larger than those in the SKAP2-injected mouse.
Discussion
The present study revealed that overexpression of AP-2a in human ovarian cancer cell lines decreases peritoneal dissemination in nude mice, with significant prolongation of survival. This is the first study to demonstrate improved survival with exogenously overexpressed AP2a in cancer cells. The in vitro results also showed that AP-2a overexpression suppressed growth to 76-79% by MTS proliferation assay, which was confirmed by BrdU assay. This effect of AP-2a on growth suppression was significant but rather small, which may be associated with the result that AP-2a overexpression did not induce cell cycle arrest (data not shown). AP-2a has been demonstrated to play a suppressive role on proliferation in other cancer cells, which might be dependent on p53 (McPherson et al., 2002) . A little effect on growth by the transfection of AP-2a into SKOV3 cells might result from that SKOV3 did not express p53 (Vikhanskaya et al., 1994) . Then, we examined whether AP-2a might affect the expression of erbB2, which was expressed in 20-40% of ovarian cancer (Agus et al., 2000) , and has been reported to be related to cell proliferation in breast cancer. Unexpectedly, we could not demonstrate that AP-2a regulated the expression of erbB2. However, AP2a significantly downregulated the phosphorylation levels of erbB2. Further, we have shown that the activation of the Akt and ERK1/2 pathways, the cell survival and growth signal pathways, was inhibited by AP-2a transfection. The Akt/ERK pathways have been reported to be activated by the phosphorylation of erbB2 (Venkateswarlu et al., 2002) . The decreased phosphorylation level of erbB2 would be responsible for the inactivation of the Akt/ERK pathways in AP-2a-overexpressed cells. To our knowledge, this is the first report to describe the relationship between AP-2a and the Akt/ERK pathways. Others have also demonstrated that AP-2 may negatively regulate several genes involved in the progression of ovarian cancer, such as c-myc (Gaubatz et al., 1995) , which may also account for the growth inhibition by AP-2a.
The in vitro studies revealed that AP-2a overexpression suppressed invasiveness to 4.1-4.3% by Matrigel invasion assay, which would account for the decreased metastatic potential in nude mice. To further confirm it, we showed that AP-2a overexpression increased Ecadherin, which is a transmembrane glycoprotein correlated with the suppression of invasion through the compact aggregation of cancer cells (Luo et al., 1999) . On the other hand, AP-2a overexpression decreased MMP-2 activity, which is involved in tumor invasion and establishment of metastasis in ovarian cancer (Schmalfeldt et al., 2001) . Several studies have revealed that AP-2 is concerned with the regulation of both E-cadherin (West-Mays et al., 2003) and MMP-2 (Gershenwald et al., 2001) , which was also demonstrated in our study, and thus we strongly assumed that increased E-cadherin expression and decreased MMP-2 activity might be contributed to a suppressive effect of AP-2a on invasiveness and metastasis in ovarian cancer. Further, previous reports have already shown that E-cadherin transfection into E-cadherin-negative cells (1) changed the morphology from spindle to epitheloid shape, (2) decreased invasion ability, and (3) decreased MMP-2 activity (Luo et al., 1999; Nawrocki-Raby et al., 2003) . On the other hand, it was reported that inhibition of MMP prevented cadherin ectodomain cleavage, which resulted in the stabilization of cadherin-mediated cell-to-cell contacts (Ho et al., 2001) . Thus, E-cadherin and MMP-2 in AP-2a-overexpressed cells could be controlled not only by AP-2a but also by the counter activation between E-cadherin and MMP-2. Our study demonstrated that decreased AP-2a expression involved in the mechanism by which ovarian epithelial cells displaying a peritoneal metastatic phenotype. The previous immunohistochemical analysis has revealed that high AP-2a expression was associated with significant survival advantage (Anttila et al., 2000) . Interestingly, AP-2a is located on chromosome 
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The levels of p-Akt and p-ERK1/2, respectively. Both p-Akt (60 kDa) and p-ERK1/2 (44 kDa/42 kDa) were clearly detected in SKOV3 and SKpSG5 cells; however, they were apparently decreased in SKAP2 cells (upper panel). The nonphosphorylated Akt, ERK1/2 and b-actin proteins were at almost the same level among these cell lines (middle and lower panel). (d and f) The histogram represents the relative activity of Akt and ERK1/2 (30 min), respectively. There were significant decreases in p-Akt and p-ERK1/2 activities in SKAP2 cells. For all figures, the experiments were performed at least in triplicate AP-2a plays a tumor suppressive role in ovarian cancer S Sumigama et al 6p, where loss of heterozygosity has been detected in 62% of primary ovarian cancer (Foulkes et al., 1993) . It was suggested that at least two regions of chromosome 6 are important for ovarian epithelial carcinogenesis, one of which is close to the centromere of chromosome 6 (Cliby et al., 1993) , proximal to the AP-2 gene.
Previous reports have provided several lines of evidence that AP-2 plays a pivotal role in tumor growth and metastasis. Bar-Eli (1997) reported that AP-2 transfectants increased the expression of melanoma adhesion molecules MCAM/MUC18 and decrease the tyrosine-kinase receptor c-KIT , which influenced the metastatic potential of melanoma. Thus, they proposed that loss of AP-2 represented a crucial event in the transition of melanoma cells to a metastatic phenotype (Gaubatz et al., 1995) . Conversely, AP-2 transactivate the expression of erbB2 and erbB3 (Zhu and Domann, 2002; Vernimmen et al., 2003) as mentioned above and insulin-like growth factor I receptor in breast cancer (Turner et al., 1998) . Thus, the function of AP-2 in tumorigenesis seems to depend on the kinds of cancer. In this study, we indicated that AP-2a also functions as a tumor suppressor in ovarian cancer, supporting the clinical report that high AP-2a expression confers a survival advantage (Anttila et al., 2000) .
AP-2a introduction may contribute to other molecular events to acquire the low potential phenotype. Interestingly, expression patterns of AP-2a in various ovarian cancer cell lines in this study were strikingly similar to those of dipeptidyl peptidase IV (DPPIV), a cell-surface aminopeptidase that was originally characterized as a T-cell differentiation antigen existing on epithelial cells of various tissues (Mizutani et al., 1985) . SKOV3 and HRA showed very low expression of AP-2a and DPPIV, while TAOV, NOS2 and NOS4 displayed relatively high expression (Kajiyama et al., 2002) . Furthermore, AP-2a overexpression changed cell morphology from a long-bipolar, spindle shape to a cobblestone appearance, which was also observed in DPPIV-overexpressing cells (Kajiyama et al., 2002) . The promoter region of human DPPIV gene is reported to be GC rich (Qvist et al., 1998) , suggesting a possible binding site for AP-2. We are now studying the relationship between DPPIV and AP-2a.
In conclusion, AP-2a overexpression suppresses the metastatic potential of ovarian cancer cells in vitro and in vivo. Loss of endogenous AP-2a expression in ovarian cancer seems likely to promote lethal intraperitoneal dissemination, and introducing the AP-2a gene into cancer cells might offer a new therapeutic strategy for ovarian cancer.
Materials and methods
Cell culture
The human ovarian cancer cell lines, SKOV3, HRA, TAOV, NOS2 and NOS4, were derived from serous adenocarcinoma. SKOV3 and HRA cells were generously donated by the Memorial Sloan-Kettering Cancer Research Laboratory and Dr Kikuchi (Defense Medical University, Tokorozawa, Japan), respectively. TAOV (Mizuno et al., 1992) , NOS2 (Kikkawa et al., 1993) and NOS4 (Hayakawa et al., 1999) cells were established in our institute. Cells were maintained in RPMI-1640 supplemented with 10% FCS and penicillinstreptomycin and incubated at 371C in a humidified atmosphere of 5% CO 2 .
Plasmid construction and stable transfection SKOV3 cells were transfected with either the AP-2a expression vector, pSG5-neo-AP-2a (SKAP2 cell), or the control vector, pSG5-neo (SKpSG5 cell) (Buettner et al., 1993) using Lipofectamine according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Stable transfectants were selected by growth in the media supplemented with 400 mg/ml of G418 (Sigma-Aldrich, St Louis, MO, USA) and clones resistant to G418 were obtained.
Transient transfection and CAT assays
The CAT reporter construct, A2BCAT, contained three copies of the AP-2 binding sequence 5 0 -CTGAC CGCCC GCGGC CCGT-3 0 toward the TATA box, while BCAT contained only the TATA box, as reported previously (Williams and Tjian, 1991) . We cotransfected 3.0 Â 10 6 cells in 60 mm culture dishes with 2.5 mg of reporter CAT construct and 2.5 mg of a 
Western blot analysis
After achieving 70% confluency, cells were treated with lysis buffer (50 mM HEPES-KOH (pH 7.8), 420 mM KCl, 0.1 mM EDTA (pH 8.0), 1% Nonidet P-40, 5 mM MgCl 2 , 2% glycerol, 1 mM dithiothreitol, 0.5 mM phenylmethysulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml pepstain, 2 mg/ml leupeptin) and centrifuged at 12 000 g for 15 min. After measuring concentration using a BCA Protein Assay Kit (Pierce Biotechnology, Rockfold, IL, USA), an aliquot of supernatant (20 mg) was separated under 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. AP-2a, E-cadherin and b-actin proteins were visualized using an ECL Plus Western blotting detection kit (Amersham Biosciences, Buckinghamshire, UK) with anti-AP-2a, anti-E-cadherin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-b-actin antibody (Abcam, Cambridge, UK), respectively. For the detection of phosphorylated erbB2, Akt and ERK1/2, cells were maintained in RPMI-1640 without serum for 48 h to be starved and then were stimulated with 10% FCS for 15 or 30 min. Cell lysates were collected with RIPA buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA (pH 8.0), 0.1% SDS, 0.1 mM Na 3 VO 4 , 1% sodium deoxycholate). Antiphospho-erbB2, anti-phospho-Akt, anti-phospho-ERK1/2, anti-Akt, anti-ERK1/2 (Upstate Cell Signaling Solutions, Lake Placid, NY, USA) and anti-erbB2 antibodies (Oncogene Research Products, San Diego, CA, USA) were used to detect each protein.
In vitro cell proliferation assay SKOV3, SKpSG5 and SKAP2 cells were plated in triplicate at a density of 2000 cells in 100 ml volume in 96-well plates. Cell viability was assayed using an MTS assay by Cell Titer 96 AQueous One Solution Cell Proliferation Assay kit (Promega) according to the manufacturer's instructions. In addition, the rate of DNA synthesis was measured by BrdU proliferation assay using the Biotrak cell proliferation ELIZA system (Amersham Biosciences) according to the manufacturer's instructions. Absorbance was measured using a microplate reader (Thermo Labsystems, Ventaa, Finland).
In vitro cell invasion assay
Cell invasion was evaluated using 24-well Matrigel invasion chambers (BD Biosciences Clontech, Palo Alto, CA, USA). Cells were suspended into the upper chamber at a density of 4.0 Â 10 4 cells in 200 ml of serum-free media. The lower chamber contained 750 ml of RPMI-1640 supplemented with 5.0% FCS as a chemoattractant. After 15 h incubation, the remaining tumor cells on the upper surface of the filters were removed by wiping with cotton swabs, and invading cells on the lower surface were stained using May-Gru¨nwald Giemsa. The number of cells on the lower surface of the filters was counted under microscopy at Â 20 magnification. Data were obtained from three individual experiments in triplicate.
Gelatin zymography
Activities of MMPs in the CM of cells were assessed using gelatin zymography, as described previously (Kajiyama et al., 2002) . Briefly, cells (4.0 Â 10 5 ) were seeded in six-well dishes and the CM was collected at 24 h. For each sample, 20 ml was electrophoresed on 10% SDS-PAGE containing 0.03% gelatin. After incubation in reaction buffer for 20 h, the gel was stained using 0.2% Coomassie Brilliant Blue.
In vivo study
Female nude mice (BALB/C) (5 weeks old) were provided by Chubu Kagaku (Nagoya, Japan) and were housed in a sterile atmosphere in isolators with food and water. SKpSG5 or SKAP2 cell suspension (1 ml) containing 1.0 Â 10 7 cells was injected intraperitoneally into five mice in each group. One mouse of each group was anatomized at 28 days after injection to evaluate intraperitoneal dissemination under anesthesia. All disseminated tumors in peritoneal cavities were measured at the longer diameter and total weight. Data are presented as mean7s.d. In addition, survival time was compared between the two groups. All animal care was in accordance with the guidelines authorized by the Nagoya University Council.
Statistical analysis
For cell proliferation assay, differences between groups were tested using analysis of variance (ANOVA) with Dunnett methods, and for cell invasion assay, ANOVA with Bonferroni/Dun methods. The Kaplan-Meier method was used to generate survival curves and comparisons were performed using log-rank tests. Values of Po0.01 were considered significant.
